A PHASE O CLINICAL TRIAL OF A NOVEL MOLECULARLY-TARGETED THERAPY FOR RECURRENT GLIOBLASTOMA PATIENTS.

PI: Nader Sanai, M.D.
Director, Division of Neurosurgical Oncology
Director, Barrow Brain Tumor Research Center
Barrow Neurological Institute